Last reviewed · How we verify

Intravitreal Bevacizumab IVB

Khyber Teaching Hospital · FDA-approved active Small molecule

Intravitreal Bevacizumab IVB is a VEGF inhibitor (monoclonal antibody) Small molecule drug developed by Khyber Teaching Hospital. It is currently FDA-approved for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye. Used for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).

At a glance

Generic nameIntravitreal Bevacizumab IVB
SponsorKhyber Teaching Hospital
Drug classVEGF inhibitor (monoclonal antibody)
TargetVEGF (Vascular Endothelial Growth Factor)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Intravitreal bevacizumab works by binding to and neutralizing VEGF, a key driver of pathological neovascularization in retinal diseases. By reducing VEGF signaling, it suppresses the growth of abnormal blood vessels and reduces vascular permeability, thereby reducing retinal edema and preventing vision loss in conditions characterized by excessive angiogenesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravitreal Bevacizumab IVB

What is Intravitreal Bevacizumab IVB?

Intravitreal Bevacizumab IVB is a VEGF inhibitor (monoclonal antibody) drug developed by Khyber Teaching Hospital, indicated for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).

How does Intravitreal Bevacizumab IVB work?

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.

What is Intravitreal Bevacizumab IVB used for?

Intravitreal Bevacizumab IVB is indicated for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO), Proliferative diabetic retinopathy (PDR).

Who makes Intravitreal Bevacizumab IVB?

Intravitreal Bevacizumab IVB is developed and marketed by Khyber Teaching Hospital (see full Khyber Teaching Hospital pipeline at /company/khyber-teaching-hospital).

What drug class is Intravitreal Bevacizumab IVB in?

Intravitreal Bevacizumab IVB belongs to the VEGF inhibitor (monoclonal antibody) class. See all VEGF inhibitor (monoclonal antibody) drugs at /class/vegf-inhibitor-monoclonal-antibody.

What development phase is Intravitreal Bevacizumab IVB in?

Intravitreal Bevacizumab IVB is FDA-approved (marketed).

What are the side effects of Intravitreal Bevacizumab IVB?

Common side effects of Intravitreal Bevacizumab IVB include Endophthalmitis, Retinal detachment, Cataract progression, Intraocular pressure elevation, Floaters/vitreous opacities.

What does Intravitreal Bevacizumab IVB target?

Intravitreal Bevacizumab IVB targets VEGF (Vascular Endothelial Growth Factor) and is a VEGF inhibitor (monoclonal antibody).

Related